Naproxcinod results increase confidence in NicOx - update
This article was originally published in Scrip
Executive Summary
NicOx is confident in its future growth potential after announcing positive results from the second of its three Phase III studies with naproxcinod, the first anti-inflammatory in the class of COX-inhibiting nitric oxide donators. Naproxcinod met its three primary pain endpoints as well as its main secondary endpoint (ScripOnline, September 17th, 2008).